Effect of combination treatment of S–amlodipine with peroxisome proliferator-activated receptor agonists on metabolic and cardiovascular parameters in Zucker fa/fa rats

Diabetology & Metabolic Syndrome

Mukul Jain³  MK Unnikrishnan⁴  Arvind Semwal⁴  Onkar Kulkarni⁵  Subhasis Roy³  Rinku Umrani³  Jeya Murugan³  Ganesh V Sangle²  Bhagat Singh¹ 

[1] Department of Clinical Neuroscience, University of Calgary, 3330 Hospital Drive, NW, Calgary, Alberta T2N4N1, Canada;Department of Physiology, University of Manitoba, Winnipeg, Canada;Department of Pharmacology, Zydus Research Centre, Ahmedabad, India;Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, Karnataka, India;Department of Pharmacy, BITS Pilani Hyderabad campus, Jawahar Nagar, Hyderabad, India

关键词: Hypertension;    Dyslipidemia;    Type 2 diabetes;    Peroxisome proliferator-activated receptors (PPARs);    Calcium channel blockers;   

Others  :  803840
DOI  :  10.1186/1758-5996-6-45

 received in 2013-11-25, accepted in 2014-03-24,  发布年份 2014

【 摘 要 】

Background

Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia, impaired glucose tolerance and insulin resistance associated with dyslipidemia and hypertension. The available drugs are not sufficiently efficacious in reducing cardiovascular risk and restoring normal glucose metabolism associated with type 2 diabetes as a mono- or a combination therapy. The present study examined the combined effects of an antihypertensive (S-Amlodipine) and an insulin-sensitizing agent, peroxisome proliferator-activated receptor (PPAR) agonists (Pioglitazone and Ragaglitazar), on cardiovascular risk factors in aged diabetic and insulin-resistant Zucker fa/fa rats.

Methods

Following combination treatment for 14 days, blood pressure (BP), serum glucose, total cholesterol and triglycerides were measured. Aortic ring study was conducted to determine the effect of combination treatments on phenylephrine-induced vasoconstriction and acetylcholine (Ach)-induced vasorelaxation.

Results

In combination, S-Amlodipine and Pioglitazone significantly reduced blood glucose (115.1 ± 6.6 vs. 81.7 ± 4.2), BP (184.4 ± 5.0 vs. 155.1 ± 5.0), serum triglycerides (362.5 ± 47.5 vs. 211.1 ± 23.7) and glucose intolerance when compared with vehicle treated Zucker fa/fa rats. Similar results were observed with the combination of S-Amlodipine and Ragaglitazar (Triglycerides, 362.5 ± 47.5 vs. 252.34 ± 27.86; BP, 184.4 ± 5.0 vs. 159.0 ± 8.0) except for serum glucose. ACh-induced vasorelaxation in aortic rings was also superior with both of the combinations compared to individual treatment. Furthermore, there was less body weight gain and food intake with S-Amlodipine and Pioglitazone combination in Zucker fa/fa rats. S-Amlodipine itself caused significant reduction in glucose (115.1 ± 6.6 vs. 89.7 ± 2.7) and BP (184.4 ± 5.0 vs. 156.1 ± 4.0) with improvement in insulin sensitivity observed through oral glucose tolerance test.

Conclusions

The results suggest that a combination of PPAR agonists and S-Amlodipine has partial benefits in improving the cardiovascular risk factors such as reduction in triglyceride levels, associated with chronic type 2 diabetes, and therefore may be utilized as an approach for addressing some of these devastating metabolic syndrome complications.

【 授权许可】

   
2014 Singh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Gerhold David L, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE Z, Bei B: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-{gamma} agonists. Endocrinol 2002, 143:2106-2118.
• [2]DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992, 15:318-368.
• [3]Consoli A: Role of liver in pathophysiology of NIDDM. Diabetes Care 1992, 15(3):430-41.
• [4]Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Juluri S, Mamidi NV, Rajagopalan R: (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 2001, 44:2675-2678.
• [5]Grobbee DE: How to ADVANCE prevention of cardiovascular complications in type 2 diabetes. Metabol 2003, 52:24-28.
• [6]Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye J, Sauerberg P, Wassermann K: Dual PPARalpha/gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 2003, 284:E841-E854.
• [7]Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
• [8]Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20:649-688.
• [9]Lowell BB: An essential regulator of adipogenesis and modulator of fat cell function: PPAR[gamma]. Cell 1999, 99:239-242.
• [10]Francis GA, Annicotte J-S, Auwerx J: PPAR-{alpha} effects on the heart and other vascular tissues. Am J Physiol Heart Circ Physiol 2003, 285:H1-H9.
• [11]Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure−activity relationship between peroxisome proliferator-activated receptor Î3 agonism and the antihyperglycemic activity of Thiazolidinediones. J Med Chem 1996, 39:665-668.
• [12]Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, Willson TM: A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. J Med Chem. 1 1999, 42:3785-3788.
• [13]Meraji S, Jayakody L, Senaratne MP, Thomson AB, Kappagoda T: Endothelium-dependent relaxation in aorta of BB rat. Diabetes 1987, 36:978-981.
• [14]Andrews TJ, Laight DW, Anggård EE, Carrier MJ: Investigation of endothelial hyperreactivity in the obese zucker rat in-situ: reversal by vitamin E. J Pharm Pharmacol 2000, 52:83-86.
• [15]Pieper GM, Peltier BA: Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995, 25:397-403.
• [16]Sarafidis PA, Lasaridis AN: Actions of peroxisome proliferator-activated receptors-[gamma] agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006, 19:646-653.
• [17]Pieper GM, Mei DA, Langenstroer P, O’Rourke ST: Bioassay of endothelium-derived relaxing factor in diabetic rat aorta. Am J Physiol 1992, 263:H676-H680.
• [18]Ruggenenti P, Ruggenenti PF, Anna I, Anelja P, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, the Bergamo Nephrologic Diabetes Complications Trial Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
• [19]Gokhale MS, Shah DH, Hakim Z, Santani DD, Goyal RK: Effect of chronic treatment with amlodipine in non-insulin-dependent diabetic rats. Pharmacol Res 1998, 37:455-459.
• [20]Pathak L, Hiremath , Kerkar PG, Manade VG: Multicentric, clinical trial of S-amlodipine 2.5 mg versus amlodipine 5 mg in the treatment of mild to moderate hypertension-a randomized, double-blind clinical trial. Assoc Physicians India 2004, 52:197-202.
• [21]Hayashi K, Gohda M, Matzno S, Kubo Y, Kido H, Yamauchi T, Nakamura N: Possible mechanism of action of AE0047, a calcium antagonist, on triglyceride metabolism. J Pharmacol Exp Ther 1997, 282:882-890.
• [22]Reaven G: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47:201-210.
• [23]Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA: Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004, 308:426-433.
• [24]Li H, Lu W, Cai W, Wang P, Zhang N, Yu C, Wang D, Liu B, Sun W: Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway. Pulm Pharmacol Therapeut 2013, 00191(13):S1094-5539.
• [25]Huang Y, Di Lorenzo A, Jiang W, Cantalupo A, Sessa WC, Giordano FJ: Hypoxia-inducible factor-1Œ ± in vascular smooth muscle regulates blood pressure homeostasis through a peroxisome proliferator‚ ÄìActivated receptor-Œ ≥ ‚ÄìAngiotensin II receptor type 1 axis. Hypertens 2013, 62:634-640.
• [26]Srinivasan PS, Hakim ZS, Santani DD, Goyal RK: Effects of chronic treatment with amlodioine in streptozotocin-diabetic and apontaneously hypertensive rats. Pharmacol Res 1997, 35:423-428.
• [27]Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA: Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 1988, 82:1848-1852.
• [28]Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P: A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999, 12:298-303.
• [29]Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki T: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998, 47:1841-1847.
• [30]Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier Elisabeth MA, Jaye M, Duverger N, Brewer H, Bryan F, Jean C, Clavey V, Staels B: PPAR-[alpha] and PPAR-[gamma] activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
• [31]Hallakou S, Doaré L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferré P: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997, 46:1393-1399.
• [32]Goel A, Agarwal N, Singh FV, Sharon A, Tiwari P, Dixit M, Pratap R, Srivastava AK, Maulik PR, Ram VJ: Antihyperglycemic activity of 2-methyl-3,4,5-triaryl-1H-pyrroles in SLM and STZ models. Bioorg Med Chem Lett 2004, 14:1089-1092.
• [33]Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000, 49:1022-1032.